NCP Inc’s Gilead Sciences GILD Stock Holding History

NCP Inc’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12	Closed	-$1.47K	–	107
2025 Q4	$1.47K	Buy	+12	New	+$1.46K	﹤0.01%	154
2025 Q2	–	Sell	-68	Closed	-$7.61K	–	83
2025 Q1	$7.61K	Hold	68	–	–	0.01%	111
2024 Q4	$6.23K	Hold	68	–	–	﹤0.01%	112
2024 Q3	$5.62K	Buy	68 +1	+1%	+$76	﹤0.01%	108
2024 Q2	$4.57K	Buy	67 +1	+2%	+$67	﹤0.01%	113
2024 Q1	$4.83K	Buy	+66	New	+$5.08K	﹤0.01%	112

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

NCP Inc's GILD Position: Q1 2026 in Review

NCP Inc sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 12 shares — an estimated $1.47K sold.

NCP Inc first reported a position in GILD in Q1 2024 and held it in 6 quarters. The position peaked at $7.61K in Q1 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

NCP Inc reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
NCP Inc sold 12 Gilead Sciences shares in Q1 2026, an estimated $1.47K.
NCP Inc first reported a position in Gilead Sciences in Q1 2024 and held it in 6 quarters.
NCP Inc's Gilead Sciences position peaked at $7.61K in Q1 2025.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on NCP Inc's 13F filing for Q1 2026, filed 8 May 2026.